<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37534643</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1671-167X</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences</Title><ISOAbbreviation>Beijing Da Xue Xue Bao Yi Xue Ban</ISOAbbreviation></Journal><ArticleTitle>[Significance of IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 antibody in rheumatoid arthritis].</ArticleTitle><Pagination><StartPage>631</StartPage><EndPage>635</EndPage><MedlinePgn>631-635</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To detect serum IgA isotype of anti-v-raf murine sarcoma viral oncogene homologue B1 (BRAF) antibody levels in the rheumatoid arthritis (RA) patients in order to investigate their clinical significance in RA.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Serum samples were obtained from 61 RA patients, 21 osteoarthritis (OA) patients, 16 systemic lupus erythematosus (SLE) patients, 16 gout patients, 16 Sj&#xf6;gren's syndrome (SS) patients and 22 healthy controls. IgA isotype of anti-BRAF antibody levels in the sera were examined by enzyme-linked immunosorbent assay (ELISA). The associations between IgA isotype of anti-BRAF antibody levels and the clinical features including age, disease duration and laboratory parameters including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), disease activity score in 28 joints (DAS28), anti-cyclic citrullinated peptide (anti-CCP) antibody, immunoglobulin and BRAF protein levels in the RA patients were evaluated. Data analyses were performed by using SPSS 19.0 program.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The serum IgA isotype of anti-BRAF antibody levels in the RA patients were significantly higher than in the SLE, gout, OA patients and healthy controls, the <i>P</i> value was 0.011, &lt; 0.001, &lt; 0.001 and &lt; 0.001, respectively. The serum IgA isotype of anti-BRAF antibody levels in the SS patients were also significantly higher than in the SLE, gout, OA patients and healthy controls, the <i>P</i> value was 0.029, 0.004, 0.001 and &lt; 0.001, respectively. However, there was no difference between the RA and SS patients (<i>P</i>=0.762). IgA isotype of anti-BRAF antibody was measurable in the RA patients without RF, anti-CCP antibody or anti-keratin antibody (AKA) antibodies. The levels of IgA isotype of anti-BRAF antibody in the RA patients did not show any correlation with clinical features such as age and disease duration or laboratory parameters including ESR, CRP, RF, DAS28, anti-CCP antibody, immunoglobulin and BRAF protein levels. Compared with the clinical features and laboratory indexes of normal and elevated levels of IgA isotype of anti-BRAF antibody groups in the RA patients, there was no significant differences between the two groups in age, disease duration, ESR, CRP, RF, DAS28, anti-CCP antibody, immunoglobulin or BRAF protein levels.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The elevated level of IgA isotype of anti-BRAF antibody in the RA patients showed that IgA isotype of anti-BRAF antibody might play a role in the pathogenesis of RA. Furthermore, detection of IgA isotype of anti-BRAF antibody in the serum negative RA patients showed that it might be helpful for the diagnosis of the serum negative RA patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Y J</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>J X</ForeName><Initials>JX</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X Y</ForeName><Initials>XY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Beijing Da Xue Xue Bao Yi Xue Ban</MedlineTA><NlmUniqueID>101125284</NlmUniqueID><ISSNLinking>1671-167X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075422">Anti-Citrullinated Protein Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>9009-79-4</RegistryNumber><NameOfSubstance UI="D012217">Rheumatoid Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007070">Immunoglobulin A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010456">Peptides, Cyclic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075422" MajorTopicYN="N">Anti-Citrullinated Protein Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="Y">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012217" MajorTopicYN="N">Rheumatoid Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012859" MajorTopicYN="Y">Sjogren's Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010003" MajorTopicYN="Y">Osteoarthritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009857" MajorTopicYN="N">Oncogenes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007070" MajorTopicYN="N">Immunoglobulin A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006073" MajorTopicYN="Y">Gout</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010456" MajorTopicYN="N">Peptides, Cyclic</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText Label="&#x76ee;&#x7684;">&#x68c0;&#x6d4b;&#x7c7b;&#x98ce;&#x6e7f;&#x5173;&#x8282;&#x708e;(rheumatoid arthritis&#xff0c;RA)&#x60a3;&#x8005;&#x8840;&#x6e05;&#x4e2d;IgA&#x578b;&#x6297;&#x9f20;&#x79d1;&#x8089;&#x7624;&#x75c5;&#x6bd2;&#x764c;&#x57fa;&#x56e0;&#x540c;&#x6e90;&#x7269;B1(v-raf murine sarcoma viral oncogene homologue B1&#xff0c;BRAF)&#x6297;&#x4f53;&#x6c34;&#x5e73;&#xff0c;&#x63a2;&#x8ba8;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x5728;RA&#x8840;&#x6e05;&#x4e2d;&#x7684;&#x8868;&#x8fbe;&#x53ca;&#x5176;&#x4e0e;&#x4e34;&#x5e8a;&#x6307;&#x6807;&#x7684;&#x76f8;&#x5173;&#x6027;&#x3002;</AbstractText><AbstractText Label="&#x65b9;&#x6cd5;">&#x7eb3;&#x5165;RA&#x60a3;&#x8005;61&#x4f8b;&#x3001;&#x5e72;&#x71e5;&#x7efc;&#x5408;&#x5f81;(Sj&#xf6;gren&#x2019;s syndrome&#xff0c;SS)&#x60a3;&#x8005;16&#x4f8b;&#x3001;&#x7cfb;&#x7edf;&#x6027;&#x7ea2;&#x6591;&#x72fc;&#x75ae;(systemic lupus erythematosus&#xff0c;SLE)&#x60a3;&#x8005;16&#x4f8b;&#x3001;&#x75db;&#x98ce;&#x60a3;&#x8005;16&#x4f8b;&#x3001;&#x9aa8;&#x5173;&#x8282;&#x708e;(osteoarthritis&#xff0c;OA)&#x60a3;&#x8005;21&#x4f8b;&#x3001;&#x5065;&#x5eb7;&#x5bf9;&#x7167;22&#x4f8b;&#xff0c;&#x4ee5;&#x91cd;&#x7ec4;&#x7684;BRAF&#x86cb;&#x767d;&#x4e3a;&#x6297;&#x539f;&#xff0c;&#x5e94;&#x7528;&#x9176;&#x8054;&#x514d;&#x75ab;&#x5438;&#x9644;&#x8bd5;&#x9a8c;(enzyme-linked immunosorbent assay&#xff0c;ELISA)&#x65b9;&#x6cd5;&#x68c0;&#x6d4b;&#x6240;&#x6709;&#x60a3;&#x8005;&#x8840;&#x6e05;&#x4e2d;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x6c34;&#x5e73;&#xff0c;&#x5206;&#x6790;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x4e0e;RA&#x60a3;&#x8005;&#x7684;&#x4e34;&#x5e8a;&#x548c;&#x5b9e;&#x9a8c;&#x5ba4;&#x6307;&#x6807;&#x7684;&#x5173;&#x7cfb;&#x3002;&#x91c7;&#x7528;SPSS 19.0&#x8fdb;&#x884c;&#x7edf;&#x8ba1;&#x5b66;&#x5206;&#x6790;&#x3002;</AbstractText><AbstractText Label="&#x7ed3;&#x679c;">RA&#x7ec4;&#x60a3;&#x8005;&#x8840;&#x6e05;&#x4e2d;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x6ef4;&#x5ea6;&#x660e;&#x663e;&#x9ad8;&#x4e8e;SLE&#x7ec4;(<i>P</i>=0.011)&#x3001;&#x75db;&#x98ce;&#x7ec4;(<i>P</i> &lt; 0.001)&#x3001;OA&#x7ec4;(<i>P</i> &lt; 0.001)&#x548c;&#x5065;&#x5eb7;&#x5bf9;&#x7167;&#x7ec4;(<i>P</i> &lt; 0.001)&#x3002;RA&#x7ec4;&#x4e0e;SS&#x7ec4;&#x76f8;&#x6bd4;&#xff0c;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x6c34;&#x5e73;&#x5dee;&#x5f02;&#x65e0;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;(<i>P</i>=0.762)&#x3002;&#x5728;&#x7c7b;&#x98ce;&#x6e7f;&#x56e0;&#x5b50;&#x3001;&#x6297;&#x73af;&#x74dc;&#x6c28;&#x9178;&#x591a;&#x80bd;(cyclic citrullinated peptide&#xff0c;CCP)&#x6297;&#x4f53;&#x3001;&#x6297;&#x89d2;&#x86cb;&#x767d;&#x6297;&#x4f53;&#x9634;&#x6027;&#x7684;RA&#x60a3;&#x8005;&#x4e2d;&#x4ecd;&#x53ef;&#x4ee5;&#x68c0;&#x6d4b;&#x5230;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x3002;RA&#x60a3;&#x8005;&#x8840;&#x6e05;&#x4e2d;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x6c34;&#x5e73;&#x4e0e;&#x4e34;&#x5e8a;&#x53ca;&#x5b9e;&#x9a8c;&#x5ba4;&#x6307;&#x6807;&#x65e0;&#x76f8;&#x5173;&#x6027;&#x3002;&#x5c06;RA&#x60a3;&#x8005;&#x5206;&#x4e3a;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x5347;&#x9ad8;&#x7ec4;&#x53ca;&#x6b63;&#x5e38;&#x7ec4;&#x8fdb;&#x884c;&#x6bd4;&#x8f83;&#xff0c;&#x7ed3;&#x679c;&#x663e;&#x793a;&#x4e24;&#x7ec4;&#x5728;&#x4e34;&#x5e8a;&#x53ca;&#x5b9e;&#x9a8c;&#x5ba4;&#x6307;&#x6807;&#x4e0a;&#x5dee;&#x5f02;&#x5747;&#x65e0;&#x7edf;&#x8ba1;&#x5b66;&#x610f;&#x4e49;&#x3002;</AbstractText><AbstractText Label="&#x7ed3;&#x8bba;">RA&#x60a3;&#x8005;&#x8840;&#x6e05;&#x4e2d;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x6c34;&#x5e73;&#x663e;&#x8457;&#x9ad8;&#x4e8e;SLE&#x3001;&#x75db;&#x98ce;&#x3001;OA&#x53ca;&#x5065;&#x5eb7;&#x5bf9;&#x7167;&#x7ec4;&#xff0c;&#x4e14;&#x53ef;&#x5728;&#x7c7b;&#x98ce;&#x6e7f;&#x56e0;&#x5b50;&#x3001;&#x6297;CCP&#x6297;&#x4f53;&#x53ca;&#x6297;&#x89d2;&#x86cb;&#x767d;&#x6297;&#x4f53;&#x9634;&#x6027;&#x7684;RA&#x60a3;&#x8005;&#x4e2d;&#x5347;&#x9ad8;&#xff0c;&#x63d0;&#x793a;IgA&#x578b;&#x6297;BRAF&#x6297;&#x4f53;&#x53ef;&#x80fd;&#x53c2;&#x4e0e;RA&#x7684;&#x53d1;&#x75c5;&#x8fc7;&#x7a0b;&#xff0c;&#x4e14;&#x53ef;&#x80fd;&#x6709;&#x52a9;&#x4e8e;&#x8840;&#x6e05;&#x9634;&#x6027;RA&#x60a3;&#x8005;&#x7684;&#x8bca;&#x65ad;&#x3002;</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IgA isotype of anti-BRAF antibody</Keyword><Keyword MajorTopicYN="N">Rheumatoid arthritis</Keyword><Keyword MajorTopicYN="N">v-raf murine sarcoma viral oncogene homologue B1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37534643</ArticleId><ArticleId IdType="pmc">PMC10398764</ArticleId><ArticleId IdType="doi">10.19723/j.issn.1671-167X.2023.04.010</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ikawa S, Fukui M, Ueyama Y, et al. B-raf, a new member of the raf family is activated by DNA rearrangement. Mol Cell Biol. 1988;8(6):2651&#x2013;2654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC363468</ArticleId><ArticleId IdType="pubmed">3043188</ArticleId></ArticleIdList></Reference><Reference><Citation>Karhryn I. Raf protiens and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta. 2003;1653(1):25&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">12781369</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo SF, Fang RY, Hsieh HL, et al. Involvement of MAPKs and NF-kappaB in tumor necrosis factor alpha-induced vascular cell adhesion molecule l expression in human rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 2010;62(1):105&#x2013;116. doi: 10.1002/art.25060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.25060</ArticleId><ArticleId IdType="pubmed">20039412</ArticleId></ArticleIdList></Reference><Reference><Citation>Schett G, Zwerina J, Firestein G. The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):909&#x2013;916. doi: 10.1136/ard.2007.074278.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2007.074278</ArticleId><ArticleId IdType="pmc">PMC2754165</ArticleId><ArticleId IdType="pubmed">17827184</ArticleId></ArticleIdList></Reference><Reference><Citation>Auger I, Balandraud N, Rak J, et al. New autoantigens in rheumatoid arthritis (RA): Screening 8268 protein arrays with sera from patients with RA. Ann Rheum Dis. 2009;68(4):591&#x2013;594. doi: 10.1136/ard.2008.096917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.096917</ArticleId><ArticleId IdType="pubmed">18957483</ArticleId></ArticleIdList></Reference><Reference><Citation>Szekanecz Z, So&#xf3;s L, Szab&#xf3; Z, et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: As good as it gets? Clin Rev Allergy Immunol. 2008;34(1):26&#x2013;31. doi: 10.1007/s12016-007-8022-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-007-8022-5</ArticleId><ArticleId IdType="pubmed">18270854</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang XP, Cheng QY, Gu MM, et al. Diagnostic accuracy of anti-keratin antibody for rheumatoid arthritis: A meta-analysis. Clin Rheumatol. 2019;38(7):1841&#x2013;1849. doi: 10.1007/s10067-019-04464-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-019-04464-x</ArticleId><ArticleId IdType="pubmed">30810911</ArticleId></ArticleIdList></Reference><Reference><Citation>Charpin C, Martin M, Balandraud N, et al. Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R194. doi: 10.1186/ar3165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3165</ArticleId><ArticleId IdType="pmc">PMC2991030</ArticleId><ArticleId IdType="pubmed">20955560</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x5f20; &#x971e;, &#x8d75; &#x91d1;&#x971e;, &#x5b59; &#x7433;, et al. &#x6297;&#x9f20;&#x79d1;&#x8089;&#x7624;&#x75c5;&#x6bd2;&#x764c;&#x57fa;&#x56e0;&#x540c;&#x6e90;&#x7269;B1&#x6297;&#x4f53;&#x7684;&#x68c0;&#x6d4b;&#x53ca;&#x5176;&#x5728;&#x7c7b;&#x98ce;&#x6e7f;&#x5173;&#x8282;&#x708e;&#x8bca;&#x65ad;&#x4e2d;&#x7684;&#x610f;&#x4e49;. &#x5317;&#x4eac;&#x5927;&#x5b66;&#x5b66;&#x62a5;(&#x533b;&#x5b66;&#x7248;) 2012;44(2):195&#x2013;198.</Citation></Reference><Reference><Citation>Woof JM, Mestecky J. Mucosal immunoglobulins. Immunol Rev. 2005;206:64&#x2013;82. doi: 10.1111/j.0105-2896.2005.00290.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0105-2896.2005.00290.x</ArticleId><ArticleId IdType="pubmed">16048542</ArticleId></ArticleIdList></Reference><Reference><Citation>Thalhamer T, McGrath MA, Hamett MM. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008;47(4):409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">18187523</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>